Literature DB >> 27178147

Case of hypophysitis caused by nivolumab.

Masashi Ishikawa1, Kohei Oashi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27178147     DOI： 10.1111/1346-8138.13437

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  9 in total

1.  A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency.

Authors:  Yozo Sato; Yosuke Tanaka; Mitsunori Hino; Masahiro Seike; Akihiko Gemma
Journal:  Respir Med Case Rep       Date:  2019-01-28

Review 2.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

3.  Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.

Authors:  Kazuhiko Takaya; Miwa Sonoda; Ayako Fuchigami; Toru Hiyoshi
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

4.  Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.

Authors:  Satoshi Yamagata; Kazunori Kageyama; Shinobu Takayasu; Yuko Asari; Koshi Makita; Ken Terui; Makoto Daimon
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

Review 5.  Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention.

Authors:  Benxia Zhang; Xue Li; Tao Yin; Diyuan Qin; Yue Chen; Qizhi Ma; Pei Shu; Yongsheng Wang
Journal:  J Oncol       Date:  2022-01-18       Impact factor: 4.375

6.  Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab.

Authors:  Wataru Omata; Satoko Nakamura; Chie Urasaki; Hiromichi Morita; Hiroki Funaishi; Kazuki Kobayashi; Hisashi Koide; Arata Tsutsumida; Hiroyuki Matsue
Journal:  Case Rep Dermatol       Date:  2022-03-21

7.  Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

Authors:  Tomoko Kobayashi; Shintaro Iwama; Yoshinori Yasuda; Norio Okada; Taku Tsunekawa; Takeshi Onoue; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Yoshiaki Morishita; Motomitsu Goto; Hidetaka Suga; Ryoichi Banno; Kenji Yokota; Tetsunari Hase; Masahiro Morise; Naozumi Hashimoto; Masahiko Ando; Hitoshi Kiyoi; Momokazu Gotoh; Yuichi Ando; Masashi Akiyama; Yoshinori Hasegawa; Hiroshi Arima
Journal:  J Endocr Soc       Date:  2018-02-06

Review 8.  Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.

Authors:  Nobumasa Ohara; Kazumasa Ohashi; Toshiya Fujisaki; Chiyumi Oda; Yohei Ikeda; Yuichiro Yoneoka; Takehisa Hashimoto; Go Hasegawa; Kazuo Suzuki; Toshinori Takada
Journal:  Intern Med       Date:  2017-11-20       Impact factor: 1.271

9.  Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.

Authors:  Yuka Mishima; Takahiro Fukaishi; Naohiko Inase; Susumu Isogai
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.